Skip to main content

Advertisement

SpringerLink
Log in

Diammine Dicarboxylic Acid Platinum Enhances Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells through Induction of Apoptosis and S-Phase Cell Arrest

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

Polysaccharides such as chondroitin play a potent role in tumor growth, tissue repair and angiogenesis. These properties make chondroitin a good candidate for novel drug delivery systems. Diammine dicarboxylic acid platinum (DDAP), a novel polymeric platinum compound, was developed by conjugating the platinum analogue to aspartate–chondroitin for drug delivery to tumor cells. DDAP improves platinum solubility which may reduce systemic toxicity and be more efficacious than cisplatin in killing tumor cells.

Methods

We tested and compared the cytotoxic effects of DDAP and CDDP on the platinum-sensitive 2008 and A2780 ovarian cancer cell lines and their platinum-resistant sublines 2008.C13 and A2780cis; we also investigated DDAP’s mechanism of action.

Results

In the platinum-sensitive cell lines, the cytotoxic effects of DDAP and CDDP were comparable. However, in the platinum-resistant sublines, significantly greater cell-growth inhibition was induced by DDAP than by CDDP, especially at lower doses. DDAP also induced more apoptosis than CDDP did in the 2008.C13 subline, which was partially mediated by the caspase 3-dependent pathway. In addition, lower (but not higher) doses of DDAP arrested 90% of S-phase 2008.C13 cells, which might be associated with up-regulation of p21 and maintenance of low cyclin A expression. Furthermore, greater cellular uptake of DDAP was seen in platinum-resistant than in platinum-sensitive ovarian cancer cells.

Conclusions

Low-dose DDAP enhances drug delivery to platinum-resistant ovarian cancer cells and substantially inhibits their growth by inducting apoptosis and arresting cells in the S-phase, suggesting that DDAP may overcome platinum resistance in ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Fig. 7.
Fig. 8.

Similar content being viewed by others

REFERENCES

  1. A. Jemal, L. X. Clegg, E. Ward, L. A. Ries, X. Wu, P. M. Jamison, P. A. Wingo, H. L. Howe, R. N. Anderson, and B. K. Edwards. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 101:3–27 (2004).

    Article  PubMed  Google Scholar 

  2. J. J. Kavanagh, S. Pecoreli, A. Dipertrillo, and N. Einhorn. Chemotherapy in advanced ovarian cancer. Blackwell Scientific, Cambrige, MA, 1998.

    Google Scholar 

  3. W. P. McGuire, W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge, K. Y. Look, D. L. Clarke-Pearson, and M. Davidson. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments]. N Engl J Med. 334:1–6 (1996).

    Article  PubMed  CAS  Google Scholar 

  4. M. J. Piccart, H. Lamb, and J. B. Vermorken. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol. 12:1195–1203 (2001).

    Article  PubMed  CAS  Google Scholar 

  5. J. T. Thigpen. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol. 27:11–16 (2000).

    PubMed  CAS  Google Scholar 

  6. G. Giaccone. Clinical perspectives on platinum resistance. Drugs. 59(Suppl 4):9–17 (2000)discussion 37–18.

    Article  PubMed  CAS  Google Scholar 

  7. S. Manic, L. Gatti, N. Carenini, G. Fumagalli, F. Zunino, and P. Perego. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets. 3:21–29 (2003).

    Article  PubMed  CAS  Google Scholar 

  8. C. Balch, T. H. Huang, R. Brown, and K. P. Nephew. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 191:1552–1572 (2004).

    Article  PubMed  CAS  Google Scholar 

  9. W. P. McGuire, and R. F. Ozols. Chemotherapy of advanced ovarian cancer. Semin Oncol. 25:340–348 (1998).

    PubMed  CAS  Google Scholar 

  10. W. P. McGuire 3rd, and M. Markman. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 89(Suppl 3):S3–8 (2003).

    Article  PubMed  CAS  Google Scholar 

  11. M. A. Fuertes, J. Castilla, C. Alonso, and J. M. Perez. Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anti-Canc Agents. 2:539–551 (2002).

    Article  CAS  Google Scholar 

  12. N. J. Moreland, M. Illand, Y. T. Kim, J. Paul, and R. Brown. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 59:2102–2106 (1999).

    PubMed  CAS  Google Scholar 

  13. Z. H. Siddik. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279 (2003).

    Article  PubMed  CAS  Google Scholar 

  14. F. M. Muggia, and G. Los. Platinum resistance: laboratory findings and clinical implications. Stem Cells. 11:182–193 (1993).

    Article  PubMed  CAS  Google Scholar 

  15. A. de Graeff, R. J. Slebos, and S. Rodenhuis. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol. 22:325–332 (1988).

    Article  PubMed  Google Scholar 

  16. M. J. McKeage. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs. 14:1033–1046 (2005).

    Article  PubMed  CAS  Google Scholar 

  17. G. Biagini, A. Pugnaloni, A. Damadei, A. Bertani, A. Belligolli, V. Bicchiega, and R. Muzzarelli. Morphological study of the capsular organization around tissue expanders coated with N-carboxybutyl chitosan. Biomaterials. 12:287–291 (1991).

    Article  PubMed  CAS  Google Scholar 

  18. J. S. Pieper, P. B. van Wachem, M. J. A. van Luyn, L. A. Brouwer, T. Hafmans, J. H. Veerkamp, and T. H. van Kuppevelt. Attachment of glycosaminoglycans to collagenous matrices modulates the tissue response in rats. Biomaterials. 21:1689–1699 (2000).

    Article  PubMed  CAS  Google Scholar 

  19. M. Prabaharan, and J. F. Mano. Chitosan-based particles as controlled drug delivery systems. Drug Deliv. 12:41–57 (2005).

    Article  PubMed  CAS  Google Scholar 

  20. A. Polykratis, P. Katsoris, J. Courty, and E. Papadimitriou. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem. 280:22454–22461 (2005).

    Article  PubMed  CAS  Google Scholar 

  21. M. K. Chourasia, and S. K. Jain. Polysaccharides for colon targeted drug delivery. Drug Deliv. 11:129–148 (2004).

    Article  PubMed  CAS  Google Scholar 

  22. V. R. Sinha, and R. Kumria. Polysaccharides in colon-specific drug delivery. Int J Pharm. 224:19–38 (2001).

    Article  PubMed  CAS  Google Scholar 

  23. C. Haase, R. Bergmann, F. Fuechtner, A. Hoepping, and J. Pietzsch. l-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-l-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med. 48:2063–2071 (2007).

    Article  PubMed  CAS  Google Scholar 

  24. C. Li, J. E. Price, L. Milas, N. R. Hunter, S. Ke, D. F. Yu, C. Charnsangavej, and S. Wallace. Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res. 5:891–897 (1999).

    PubMed  CAS  Google Scholar 

  25. Y. Sedletska, M. J. Giraud-Panis, and J. M. Malinge. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents. 5:251–265 (2005).

    Article  PubMed  CAS  Google Scholar 

  26. S. Fulda, M. Los, C. Friesen, and K.M. Debatin. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer. 76:105–114 (1998).

    Article  PubMed  CAS  Google Scholar 

  27. H. Kojima, K. Endo, H. Moriyama, Y. Tanaka, E. S. Alnemri, C. A. Slapak, B. Teicher, D. Kufe, and R. Datta. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 273:16647–16650 (1998).

    Article  PubMed  CAS  Google Scholar 

  28. K. M. Henkels, and J. J. Turchi. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 59:3077–3083 (1999).

    PubMed  CAS  Google Scholar 

  29. G. D. Diaz, Q. Li, and R. H. Dashwood. Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res. 63:1254–1261 (2003).

    PubMed  CAS  Google Scholar 

  30. B. S. Cummings, G. R. Kinsey, L. J. Bolchoz, and R. G. Schnellmann. Identification of caspase-independent apoptosis in epithelial and cancer cells. J Pharmacol Exp Ther. 310:126–134 (2004).

    Article  PubMed  CAS  Google Scholar 

  31. R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H. Chen, P. J. Sadler, and D. I. Jodrell. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer. 86:1652–1657 (2002).

    Article  PubMed  CAS  Google Scholar 

  32. V. V. Ogryzko, P. Wong, and B. H. Howard. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol. 17:4877–4882 (1997).

    PubMed  CAS  Google Scholar 

  33. V. Gottifredi, K. McKinney, M. V. Poyurovsky, and C. Prives. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem. 279:5802–5810 (2004).

    Article  PubMed  CAS  Google Scholar 

  34. A. L. Gartel, and A. L. Tyner. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 246:280–289 (1999).

    Article  PubMed  CAS  Google Scholar 

  35. S. Gilfillan, E. L. Ho, M. Cella, W. M. Yokoyama, and M. Colonna. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol. 3:1150–1155 (2002).

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We thank Tamara Locke in the Department of Scientific Publications at M. D. Anderson Cancer Center for editing this manuscript, as well as Ling Chen and Richard Mendez for their assistance with the experiments. This work was supported by M. D. Anderson’s institutional grant and Core Grant (NCI grant 5P30CA016672-32).

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, Unit 1362, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler Street, Houston, Texas, 77030, USA

    Hong Zheng, Wei Hu, De-Yu Shen & John J. Kavanagh

  2. Department of Experimental Diagnostic Imaging, Unit 59, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas, 77030, USA

    Dongfang Yu, I-Chien Wei & David J. Yang

  3. Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

    Siqing Fu

  4. Department of Gynecology, Beijing Cancer Hospital, Beijing, 100036, China

    Hong Zheng

Authors
  1. Hong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongfang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. De-Yu Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Siqing Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John J. Kavanagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I-Chien Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David J. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Hu or David J. Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, H., Hu, W., Yu, D. et al. Diammine Dicarboxylic Acid Platinum Enhances Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells through Induction of Apoptosis and S-Phase Cell Arrest. Pharm Res 25, 2272–2282 (2008). https://doi.org/10.1007/s11095-008-9621-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-008-9621-4

KEY WORDS

Search

Navigation